# Efficacy and safety of venetoclax-cytarabine-homoharringtonine-based cytoreductive therapy before allogeneic hematopoietic stem cell transplantation in refractory/relapsed acute myeloid leukemia with RUNX1::RUNX1T1: a retrospective study

## TL;DR

A new treatment combining venetoclax, cytarabine, and homoharringtonine before a stem cell transplant shows promise for a rare type of leukemia.

## Contribution

A novel pre-transplant therapy for RUNX1::RUNX1T1 fusion AML is shown to be safe and effective.

## Key findings

- All five patients achieved molecular remission after the treatment.
- No patients had detectable residual disease after six months.
- All patients remained disease-free during follow-up.

## Abstract

回顾性分析2023年3月至2024年12月在上海交通大学医学院附属瑞金医院血液科接受含维奈克拉、阿糖胞苷和高三尖杉酯碱减瘤预处理桥接异基因造血干细胞移植（allo-HSCT）的5例伴RUNX1::RUNX1T1融合基因复发难治急性髓系白血病（AML）患者的临床结局。5例患者诊断至allo-HSCT中位时间为315（217～560）d，移植后6个月所有患者RUNX1::RUNX1T1融合基因定量转阴，中位转阴时间移植后2（1～6）个月。中位随访时间625（372～1 010）d，所有患者无病生存，无流式细胞术或分子学可测量残留病阳性事件，初步提示含维奈克拉、阿糖胞苷和高三尖杉酯碱减瘤预处理作为伴RUNX1::RUNX1T1融合基因复发难治AML移植前桥接方案安全有效。